MONTREAL and CHARLOTTE, N.C. , Feb. 27, 2025 (GLOBE NEWSWIRE) — Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto , will present at the TD Cowen 45 th Annual Health Care Conference , to take place from March 3-5, 2025 in Boston .
Related Posts
-
Impact of Investigational, at-Home, Self-administered, Intranasal Etripamil on the Need for Additional Medical Intervention in Patients With Supraventricular Tachycardia
-
Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Presentation
-
Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Poster
-
First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301)
